Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipocalin-2 Inhibits Osteosarcoma Cell Metastasis by Suppressing MET Expression via the MEK–ERK Pathway

25 Jun 2021

Abstract excerpt

Higher neutrophil-derived cytokine lipocalin-2 (LCN2) expression possesses a versatile role in a myriad of cancers, but little is known about the role of LCN2 on osteosarcoma metastasis. In this study, we demonstrated that higher LCN2 inhibited cellular motility, migration, and invasion of osteosarcoma cells. Moreover, using RNA sequencing technology, we found that LCN2 repressed MET gene expression in U2OS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to S100 Proteins and Annexins
Share to Traumatic Brain Injury and Neurovascular Disturbances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34202288
DOI: 10.3390/cancers13133181

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipocalin-2 Inhibits Osteosarcoma Cell Metastasis by Suppressing MET Expression via the MEK–ERK PathwayPMID 34202288Read ↗

Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progressionSemantic proximity Read ↗

Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transitionSemantic proximity Read ↗

Lipocalin 2 promotes breast cancer progression.Semantic proximity Read ↗

Lipocalin-2 negatively regulates epithelial–mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancerSemantic proximity Read ↗

Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer typesSemantic proximity Read ↗

Lipocalin 2: A multifaceted modulator of human cancerSemantic proximity Read ↗

Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.Semantic proximity Read ↗

LCN2: Versatile players in breast cancerSemantic proximity Read ↗

Knockdown of lipocalin‐2 suppresses the growth and invasion of prostate cancer cellsSemantic proximity Read ↗

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic markerSemantic proximity Read ↗

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway.Semantic proximity Read ↗

NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 geneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.